Mexico City — A roundup of key business developments in Mexico includes leadership changes at Grupo Mundo Maya and Dow, strong post-acquisition results at TRAXION, and a novel approach to pharmaceutical innovation by Synthon.
Grupo Mundo Maya Names New CEO
Grupo Mundo Maya has appointed Division General and General Staff Graduate Ricardo Flores González as its new Director General. The military officer brings 47 years of experience in the Mexican Armed Forces and previously served at the Ministry of National Defense (Sedena). Flores González will lead the state-owned enterprise as it expands its tourism and airport portfolio.
The company manages 12 airports, including the Tulum International Airport, as well as terminals in Campeche, Chetumal, Palenque, Puebla, Uruapan, Nogales, and Nuevo Laredo. Its infrastructure also includes seven hotels near archaeological sites in southeastern Mexico, four tourist parks, two museums, and a network of aviation and ground transportation fuel stations.
As part of the Plan Tulum Renace announced by President Claudia Sheinbaum, Grupo Mundo Maya will implement free access to Parque del Jaguar and set entry fees of 80 pesos for domestic visitors and 265 pesos for foreigners at the Archaeological Zone. The group strengthened its model after a brand renewal in 2025 to consolidate tourism connectivity around the Tren Maya.
Dow Names New Country Manager for Mexico
Dow has announced the appointment of Mauricio Alvarado as Country Manager for Mexico, a role he will add to his current position as Director of Communications and Public Affairs for Argentina, Colombia, Mexico, Peru, Central America, and the Caribbean. Alvarado has spent more than ten years at Dow in corporate communications, sustainability, public affairs, and stakeholder management. His appointment aims to align business priorities with the industrial and institutional environment in Mexico. In this role, he will represent Dow’s corporate agenda in Mexico, coordinate operational units, and work with local and regional leadership to execute the global strategy. Dow considers Mexico a strategic market due to its manufacturing capacity, talent quality, and trade integration within North American and Latin American industrial chains.
TRAXION Exceeds Synergy Expectations After Solistica Acquisition
One year after incorporating Solistica, TRAXION has demonstrated how a clear strategy can turn an acquisition into a competitive advantage. Under CEO Aby Lijtszain, the company surpassed initial synergy projections and consolidated a logistics platform with greater coverage and operational capacity. In a context of cost pressure and increasingly complex supply chains, TRAXION reported a 36.2% increase in consolidated revenue and a 124.1% jump in its logistics and technology segment. The integration reflects a bet on strengthening capabilities to compete in a demanding market.
Synthon Takes a New Approach to Pharmaceutical Innovation
While much of the pharmaceutical industry focuses on discovering new molecules, Synthon — which has operated in Mexico since 2010 and now identifies the country as a strategic market — has found another path to innovation: perfecting bioequivalence research using artificial intelligence, real-world evidence, and harmonized regulatory models. This approach accelerates the development of new treatments, strengthens the company’s international competitiveness, and helps markets like Mexico gain faster access to high-quality medicines. Innovation here is measured not only by new products but by the ability to generate solid scientific evidence that reduces costs, maintains high quality standards, and makes the entire drug development process more efficient. This combination of science, investment, and efficiency explains why bioequivalent research has become a strategic asset for the health industry.
